ACP
GPCR icon

Altitude Crest Partners’s Structure Therapeutics GPCR Stock Holding History

Altitude Crest Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-205,166
Closed -$8.79M – 14
2024
Q1 		$8.79M Buy
+205,166
New +$8.65M 3.76% 8

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Altitude Crest Partners's GPCR Position: Q2 2024 in Review

Altitude Crest Partners sold out of Structure Therapeutics (GPCR) in Q2 2024, closing a stake of 205,166 shares — an estimated $8.79M sold.

Altitude Crest Partners first reported a position in GPCR in Q1 2024 and held it in 1 quarter. The position peaked at $8.79M in Q1 2024. 166 funds tracked by Wall St. Rank hold GPCR as of Q2 2024.

  • Altitude Crest Partners reported no remaining Structure Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 205,166 Structure Therapeutics shares in Q2 2024, an estimated $8.79M.
  • Altitude Crest Partners first reported a position in Structure Therapeutics in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Structure Therapeutics position peaked at $8.79M in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.